Allist 艾力斯
3 significant filings since 30 May 2026: 2 on dividend and 1 on earnings pre-announcement. The latest, on 27 Aug 2026: 上海艾力斯医药科技股份有限公司2026年半年度权益分派实施公告. On 17 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 46.49% from the same period a year earlier.
自 30 May 2026 起有 3 份重大公告：dividend 2 份、earnings pre-announcement 1 份。最新一份（27 Aug 2026）：上海艾力斯医药科技股份有限公司2026年半年度权益分派实施公告。17 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 46.49%。
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥469亿 | ¥63亿 | 8th highest of 158 · 158 家中第 8 高 | |
| Trailing P/E 市盈率 | 17.5x | 38.6x | 19th lowest of 112 · 112 家中第 19 低 | |
| P/B 市净率 | 5.5x | 2.5x | 32nd highest of 157 · 157 家中第 32 高 | |
| Revenue Growth 营收增速 | 39.9% | 1.6% | 19th highest of 156 · 156 家中第 19 高 | |
| Profit Growth 净利增速 | 46.6% | 1.9% | 44th highest of 158 · 158 家中第 44 高 | |
| Gross Margin 毛利率 | 94.9% | 50.2% | 3rd highest of 155 · 155 家中第 3 高 | |
| Net Margin 净利率 | 46.4% | 9.8% | 6th highest of 157 · 157 家中第 6 高 | |
| Return on Equity 净资产收益率 | 19.7% | 3.1% | 6th highest of 157 · 157 家中第 6 高 | |
| Debt to Assets 资产负债率 | 10.4% | 28.0% | 17th lowest of 158 · 158 家中第 17 低 | |
| Grade Score 评级得分 | 85 | 51 | Highest of 157 · 157 家中第 1 高 |
Statement figures are for the period to 30 Jun 2026, filed by 158 of 158 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，158 家同业中 158 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Beone Medicines 百济神州 | ¥3,979亿 | 92.9x | 11.2x | 26.8% | 14.7% | 9.9% | B |
| Hengrui Pharma 恒瑞医药 | ¥2,977亿 | 38.5x | 4.6x | -1.9% | 28.9% | 8.0% | C |
| Haisco Pharmaceutical Group 海思科 | ¥699亿 | 73.7x | 14.3x | 54.7% | 27.5% | 18.3% | B |
| CSPC Innovation Pharmaceutical 石药创新 | ¥620亿 | 60.6x | 15.8x | 208.7% | 47.9% | 38.2% | B |
| Sichuan Kelun Pharmaceutical 科伦药业 | ¥618亿 | 33.8x | 2.5x | -2.7% | 16.1% | 4.6% | C |
| Fosun Pharma 复星医药 | ¥610亿 | 18.0x | 1.3x | 4.8% | 10.5% | 3.5% | D |
| Innocare 诺诚健华 | ¥528亿 | 57.5x | 6.9x | 55.5% | 21.1% | 3.2% | C |
| Allist 艾力斯 | ¥469亿 | 17.5x | 5.5x | 39.9% | 46.4% | 19.7% | B |
| Huadong Medicine 华东医药 | ¥457亿 | 13.2x | 1.8x | 1.8% | 8.3% | 7.3% | C |
| Shenzhen Salubris Pharmaceuticals 信立泰 | ¥337亿 | 50.0x | 3.9x | 16.3% | 15.8% | 4.3% | C |
| Humanwell Healthcare ST人福 | ¥307亿 | 15.1x | 1.6x | -0.0% | 14.0% | 6.8% | C |
| Apeloa Pharmaceutical 普洛药业 | ¥293亿 | 34.5x | 4.5x | -11.4% | 10.8% | 8.1% | D |
| Zelgen 泽璟制药 | ¥288亿 | 52.5x | 16.8x | 220.9% | 53.1% | 45.7% | B |
| Dizal Pharmaceutical 迪哲医药 | ¥263亿 | — | 23.2x | 47.2% | -40.8% | -17.2% | D |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。